- Home
- PMEC vs CRVO Comparison
PMEC vs CRVO Comparison
Compare PMEC & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- CRVO
- Stock Information
- Founded
- PMEC 1984
- CRVO 2001
- Country
- PMEC Singapore
- CRVO United States
- Employees
- PMEC N/A
- CRVO N/A
- Industry
- PMEC
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- CRVO Health Care
- Exchange
- PMEC Nasdaq
- CRVO Nasdaq
- Market Cap
- PMEC 56.9M
- CRVO 67.4M
- IPO Year
- PMEC 2023
- CRVO N/A
- Fundamental
- Price
- PMEC $1.87
- CRVO $8.85
- Analyst Decision
- PMEC
- CRVO Strong Buy
- Analyst Count
- PMEC 0
- CRVO 6
- Target Price
- PMEC N/A
- CRVO $19.17
- AVG Volume (30 Days)
- PMEC 244.2K
- CRVO 118.8K
- Earning Date
- PMEC 01-01-0001
- CRVO 11-11-2025
- Dividend Yield
- PMEC N/A
- CRVO N/A
- EPS Growth
- PMEC N/A
- CRVO N/A
- EPS
- PMEC N/A
- CRVO N/A
- Revenue
- PMEC $74,349,000.00
- CRVO $7,776,968.00
- Revenue This Year
- PMEC N/A
- CRVO N/A
- Revenue Next Year
- PMEC N/A
- CRVO N/A
- P/E Ratio
- PMEC N/A
- CRVO N/A
- Revenue Growth
- PMEC 2.52
- CRVO N/A
- 52 Week Low
- PMEC $0.54
- CRVO $1.80
- 52 Week High
- PMEC $1.89
- CRVO $20.63
- Technical
- Relative Strength Index (RSI)
- PMEC 62.47
- CRVO 42.79
- Support Level
- PMEC $1.76
- CRVO $9.61
- Resistance Level
- PMEC $1.88
- CRVO $10.48
- Average True Range (ATR)
- PMEC 0.15
- CRVO 0.61
- MACD
- PMEC 0.02
- CRVO -0.15
- Stochastic Oscillator
- PMEC 96.92
- CRVO 6.85
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.